-
Breaking Ground in STS Treatment: Dr. Yuhong Zhou Champions Anti-Angiogenic TKIs at CSCO 2024
Soft tissue sarcoma (STS) is a highly heterogeneous group of tumors with complex pathology, and the benefits of first-line chemotherapy, primarily anthracycline-based, are limited. As a result, patient prognosis remains poor overall. In recent years, anti-angiogenic tyrosine kinase inhibitors (TKIs) have emerged as a promising option for second- and later-line treatments, with potential for expansion…
-
ISDE 2024 | Revolutionizing Esophageal Cancer Treatment: FLOT Regimen Emerges as a Frontrunner in ISDE 2024
In a special interview at the 20th International Society for Diseases of the Esophagus (ISDE) conference, Dr. Jens Hoeppner from Bielefeld University in Germany shared his insights on the FLOT regimen’s clinical benefits over the CROSS regimen in the treatment of locally advanced resectable esophageal adenocarcinoma. He also discussed the potential integration of immunotherapy and…
-
Advancing T-Cell Lymphoma Care: Dr. Owen O’Connor and Dr. Zhengzi Qian Discuss Emerging Therapies
In a recent discussion, Dr. Owen O’Connor and Dr. Zhengzi Qian addressed the complexities of peripheral T-cell lymphoma (PTCL) and shared insights on new therapeutic strategies. They highlighted the diversity of PTCL subtypes and the promising role of novel drugs, such as PI3K inhibitors and EZH2 inhibitors, in improving outcomes. The conversation also emphasized the…
-
Advancements in Targeted Therapies for Mycosis Fungoides and Sézary Syndrome: Dr. Lanfang Li and Professor Zhuang Weiyun Share Key Insights
In a recent interview, Dr. Lanfang Li and Professor Zhuang Weiyun from the University of California, San Francisco discussed breakthroughs in treating Mycosis Fungoides (MF) and Sézary Syndrome (SS), focusing on the efficacy of brentuximab vedotin and mogamulizumab. They highlighted the importance of targeting different disease compartments and leveraging new drugs to improve patient outcomes.…
-
Exploring Evolving Strategies for HR-Positive Breast Cancer with Dr. Virginia Kaklamani
In a recent interview, Dr. Virginia Kaklamani discussed the rapidly advancing landscape of hormone receptor-positive breast cancer treatments. With the emergence of novel medications like CDK4-6 inhibitors, oral SERDs, and PI3K/AKT pathway inhibitors, she emphasized the need for NGS testing to guide treatment decisions. Dr. Kaklamani highlighted the unique efficacy and safety profiles of alpelisib,…
-
CSCO 2024 | Dr. Yilong Wu: How to Make Targeted Therapy Decisions for NSCLC Patients with EGFR Mutations
The 27th National Conference on Clinical Oncology and the 2024 CSCO Annual Meeting, co-hosted by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Xisike Clinical Oncology Research Foundation, was held from September 25 to 29, 2024, in Xiamen. During the conference, several forums on lung cancer covered cutting-edge research and developments in the…
-
CSCO 2024丨Dr. Jun Ma Reflects on CSCO’s Glorious Journey: China’s Rise in Oncology on the Global Stage
From September 25-29, 2024, the “27th National Clinical Oncology Conference and 2024 CSCO Annual Meeting,” hosted by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Xisike Clinical Oncology Research Foundation, will be held in Xiamen. With the theme “Patient-Centered, Sharing the Future,” the conference will showcase major research advancements and developments in the…
-
CUA 2024 | Dr. Eamonn Rogers: Patient-Centered Care and Exploring Future Strategies for Prostate Cancer
Prostate cancer is a common malignant tumor in elderly men. However, with continuous advancements in diagnostic and treatment strategies, patient survival rates have improved, and patient-centered care has become a key focus in oncology. During the recent CUA Annual Meeting, Urology Frontier invited Dr. Eamonn Rogers from the National University of Ireland to share his…
Connecting Medical Expertise through Media